Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELI-SKIN
2017-003051-35Phase 3Completed
- Sponsor
- University of Bonn
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) comparing Belimumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Difference in relative change of mean RCLASI activity score at week 24. Started May 2018; status: completed.
02
Drugs
belimumab
03
Conditions
lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on 2017-003051-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003051-35.